UniQure Stock Surges 248% on Breakthrough Huntington’s Trial Results
UniQure (QURE) shares skyrocketed 248% following promising clinical trial results for its AMT-130 gene therapy, showing a 75% slowdown in Huntington's disease progression. The breakthrough triggered a parallel 59% rally in partner ClearPoint Neuro (CLPT) stock.
The biotech firm secured a $175 million non-dilutive loan facility from Hercules Capital (HTGC) to support potential commercialization. Wall Street analysts responded with multiple price target upgrades, signaling renewed confidence in the company's pipeline.